Optimization of Lamivudine Solid Dispersions by Central Composite Design

Download PDF

Lamivudine (LVD) is in BCS class II with the issue of minimal oral bioavailability. This issue can be improvised by complexing LVD with polyethylene glycol-4000 (PEG-4000) and Pluronic F-68 (PF-68) by formulation design. The attempt optimized LVD tablets through central composite design (CCD). LVD tablets will be with > 95% dissolution after 30 minitues by employing PEG-4000 and PF-68. Nine LVD tablets were formulated by design and assessed for physicochemical constraints, disintegration time, and drug dissolution. The separate and mutual consequences of PEG-4000 and PF-68 on the disintegration time of LVD tablets are highly significant (P< 0.01). Intermittent levels of PEG-4000 and more levels of PF-68 gave less time for disintegration and a greater amount of drug dissolved at the end of 30 minitues. The study concludes that PF-68 decreases the disintegration time with its concentration and PEG-4000 concentration ingresses the drug release from the formulation. The study also discovered that the optimized LVD tablet with > 97.5% dissolution in 30 minitues could be formulated by employing PEG-4000 at 30 mg and PF-68 at 44.8 mg (F-7).